Human tissue biobank has become an important resource for biomedical research. Because of the major public interest concerned, most countries have developed their own ethical governance frameworks. In this study, I focus on the norm of data release in different biobanks. How to adhere to fair access principle? What are the duties for researchers after they use the tissue and data from biobank? Can they apply patent of their research results? Whether the biobank has any power to limit the patent implementation? I compare the principles of UK. Biobank, Biobank Japan, and the law in Taiwan. My findings suggest that Taiwan should ponder the consequences of the benefit-sharing obligation, if Taiwan wants to keep in collaboration with international research community.
|Original language||Traditional Chinese|
|Number of pages||34|
|Publication status||Published - 2016|
- Human Tissue
- Material Transfer Agreement
- March-In Right
- Benefit Sharing